Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2024 Outlook
Reported updated data from ongoing Phase 1b trial in kidney transplantation demonstrating tegoprubart treatment successfully prevented kidney transplant rejection and was generally safe and well-tolerated
Related news for (ELDN)
- Breaking News: MoBot’s Latest Update as of 10/17/25 01:00 PM
- Today’s Top Performers: MoBot’s Market Review 10/17/25 12:00 PM
- Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Operating and Financial Results
- Eledon Pharmaceuticals Announces Use of Tegoprubart as Key Component of Immunosuppression Regimen in its Second Transplant of a Genetically Modified Pig Kidney into a Human
- Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2025 Outlook